Walt Disney Co vs Cassava Sciences Inc — how do they compare? Walt Disney Co trades at $97.26 (market cap $166.48B), while Cassava Sciences Inc trades at $1.12 (market cap $52.66M). The key difference: Walt Disney Co is far larger — about 3161.4× Cassava Sciences Inc's market cap, and Walt Disney Co pays a 1.56% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| DIS | FLNA | |
|---|---|---|
Market Cap | $166.48B | $52.66M |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $122.94 | $4.64 |
52-Week Low | $92.40 | $1.09 |
Enterprise Value | $208.16B | -$33.92M |
Dividend Yield | 1.56% | — |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $96.01, up 0.4% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats. Revenue grew to $94.43B in 2025 with net income surging to $12.40B. The stock shows a P/E of 15.34 and P/S of 1.77, trading below the consensus price target of $125.60. Recent news highlights advertising opportunities from major events like the Super Bowl, though box office performance for new Star Wars film raises concerns.
Outlook remains positive with analyst consensus at Buy (61.9%) and a 31% upside to target, driven by earnings momentum and theme park investments. Risks include regulatory disputes with the FCC, streaming competition, and film profitability. Cash flow trends show operational strength but negative net flows from high investing activity.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →